Impact of HTA Therapeutic Reviews on Real World Clinical Practice: The MS Society of Canada’s Perspective Dr. Karen Lee, Vice-President Research.

Slides:

Advertisements

Similar presentations

Regulatory Framework Leigh Shaw, Director.

Advertisements

NICE and National Clinical Audit Participating Trust Perspective Jean Schofield Clinical Audit Development Manager.

Regional Update 2 Financial Report 3 Governance Report 4.

OPIM 5894 Advanced Project management

Group 3: Geological storage of CO 2 Seminar I Farzad Basirat, Mattias Hogvall, Tito Maldonado, Cosima Hotzy, Daniel Sopher 12/02/2015 Group 3: Ethics in.

MIGSYS Ian Evans, Genetics Max Musicant, SOM Grant Patterson, EPH Jia Kang, Med Informatics Colin Shaw, Nursing YBPS Case Competition November 20, 2009.

How Doctors Think – Jerome Groopman, MD Chapter 9. Marketing, Money, and Medical Decisions Chapter 10. In Service of the Soul Melanie Swan MS Futures Group.

Person-centred counselling with clients presenting with drug and alcohol issues: an exploration of the client’s view Pauline Redgrift MA Client-Centred.

The Goals of Public Health An Integrated Multi-dimensional Model Christian Munthe Department of Philosophy, Göteborg University EuroPHEN, funded by the.

Pramlintide Advisory Committee July 26, 2001 Symlin ® Amylin Pharmaceuticals New Drug Application (21-332) Advisory Committee Meeting Bethesda, Maryland.

The Lidcombe Program University of Wisconsin-Stevens Point Lorrie Mittelstaedt Stacey Lamers

P.S. Reichelderfer, PhD Harwood, Maryland WHIN Meeting, 2005 Fertility Regulation Update.

Hepatitis C for the General Practitioner Morris Sherman MB BCh PhD FRCP(C) University of Toronto January 2013.

Alcohol Addiction Addiction as a Disease. The Disease Model This model looks at alcoholism as a disease for these reasons: o Alcoholism is chronic, o.

© 2014 Direct One Communications, Inc. All rights reserved. 1 Controversies in the Treatment of Multiple Sclerosis Sara S. Qureshi, MD The University of.

Towards a Shared Understanding A Forum for Dialogue and Learning.

Pharmaceutical Economics Heng-Sim Lee RPh MS Director of Pharmacy, ChiaYi Branch, Taichung Veterans General Hospital Clinical Nutritional.

Medicines Differentiation Analysis Multiple Sclerosis 18 January 2011 Mary Perkins Expected Launch Date: 3/31/2013.

Front Line Pharmacist Survey Each director of pharmacy who received an invitation to participate in the 2013/14 survey was asked to forward an to.

OPIOID SUBSTITUTION THERAPY

Social Work Prevention and Enrichment Chapter 21.

EP Show – December 2002 AFFIRM The EP Show: AFFIRM Eric Prystowsky MD Director, Clinical Electrophysiology Laboratory St Vincent Hospital The Care Group.

Dr. Avinash De Sousa.  State government aided hospital.  Private psychiatric set up – nursing home.  Out patient private practice.  Private general.

Single Patient Use of Investigational Anticancer Agents: An Industry Perspective Gerard T. Kennealey, MD Vice President, Clinical Research, Oncology AstraZeneca.

Managing type-2 diabetes in primary care in south camden - a focus on insulin conversion.

1 Exploring Alternative Antibiotic Treatment Regimens: Methodology and Implications Dr. Tabish Hazir MASCOT Study Group 2 nd ICIUM Conference 2004.

Genetics Hemophilia Presentation By Will Mcauliffe-Trefz-Genetics.

Developing New Insights Northampton Learning and Teaching Conference May 2014 Sara Simons and Sid Jeewa.

Inference for Two Population Means Goal: Hypothesis Test or Confidence interval for the “average difference” between two populations There are two designs.

Simplifying Radical Expressions Simplifying Radicals Radicals with variables.

Dennis Bourdette, MD VA MS Center of Excellence-West and

1 EFFICACY OF SHORT COURSE AMOXICILLIN FOR NON-SEVERE PNEUMONIA IN CHILDREN (Hazir T*, Latif E*, Qazi S** AND MASCOT Study Group) *Children’s Hospital,

DRUG ADDICTION TREATMENTS

Advisory Committee for Peripheral and Central Nervous System Drugs March 7, 2006 Question 1: 1.Has Biogen demonstrated natalizumab’s efficacy on reduced.

Health Technology Assessment for Pharmaceuticals and New Medical Technologies - Where are we now? The industry perspective Jenny Hughes, Director, Vaccines.

How Many Generic Lexapro Are There Lexapro Online Coupon getting off 5 mg of lexapro first two weeks of lexapro lexapro with gabapentin lexapro side effects.

Regulatory and Reimbursement Harmonization An Industry Perspective Adrian Griffin | April 2016.

 Aims to help someone manage their problems by changing how they think and act  CBT encourages people to talk about: - how people think about themselves,

A novel oral medical nutrition formula (PLP10) for the treatment of relapsing-remitting multiple sclerosis: a randomized, double-blind, placebo-controlled.

Vocab Review Observational Study: Passively observe, record, measure, question, but you don’t personally affect the situation Experiments: Active data.

Applying the New Multiple Sclerosis Guidelines to Clinical Practice

Prof. Md Sayedur Rahman Pharmacoeconomics: Bangladesh Perspective

Alcohol Rehab: Selecting The Right Program

How Alcohol Addiction Treatment Centres Have Transformed Addicts

Research Overview Jacqueline French, MD Chief Scientific Officer

OptumRx Smart Fill Program

Immune Reconstitution in MS:

Orientation to Pharmacology

Challenges in Managing Progressive Multiple Sclerosis

17-alpha Hydroxyprogesterone caproate did not reduce the rate of recurrent preterm birth in a prospective cohort study David B. Nelson, MD; Donald D. McIntire,

Oral vs IV High-Dose Methylprednisolone Are Equally Effective in MS

Are We Closer to Personalized Medicine in MS?

Should I Stay or Should I Go?

Chapter 1 Vocabulary 11.) square root 12.) radicand 13.) radical

Discussion and Concluding Remarks

Program Goals Overview Glatiramer Acetate 3 Times a Week.

Charting Progress in MS Treatment:

Treating to Target in MS

Expert Perspectives on the Clinical Use of Immune Reconstitution vs Escalation Therapy for MS.

Clinical Pearls on Hot Topics in MS

Regulatory and Reimbursement Harmonization

Module 5: Acceptability

Pregnancy in MS.

Median, Box : 25th and 75th percentiles

ISPOR 2018 Barcelona – Schedule of contributions

Championing Evidence-Based Care in Patients With Acute Low Back Pain

The ABCs of Therapeutic Strategies in Pregnancy and Multiple Sclerosis

MS, Age, and Immune Function

Data Protection, USMCA and Spending on Biologics in Canada

The Changing Face of Multiple Sclerosis: What Are the Experts Looking Forward To?

Presentation transcript:

Impact of HTA Therapeutic Reviews on Real World Clinical Practice: The MS Society of Canada’s Perspective Dr. Karen Lee, Vice-President Research

Reduce relapse disability Reduce relapse rate Reduce or stop progression Remyelination Neuroprotection 10 therapies approved in Canada with more in the pipeline 0 therapies available

Stable A BC MS Population Variability DMT Progressive MS Stable Progressive MS

“The unpredictable aspect is paramount since no 2 days are the same and no 2 hours at the same”

“ I believe I would be in a wheelchair without this medicine so I continue giving myself an injection once a day until a cure is found”

“ I would be interested in trying new drugs if they have minimal side effects and were taken orally rather than injection base.”

Views on the Therapeutic Review Assumes all people living with MS are alike, does not take into account the variability in the MS population Restrictive nature of recommendations, does not allow for choice and personalized medicine approach Focused on cost effectiveness versus the person living with MS